News about Global Pharma

Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer

The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.

Global Pharma | 08/04/2026 | By News Bureau |  122

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Global Pharma | 08/04/2026 | By News Bureau |  115

Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal

The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.

Global Pharma | 07/04/2026 | By News Bureau |  100

University of Manchester Develops SAFER-Dem Tool to Improve Dementia Patient Discharges

Researchers develop SAFER-Dem, a new care tool designed to make hospital discharge safer and more patient-centred for people living with dementia.

Global Pharma | 06/04/2026 | By News Bureau |  100

Arrowhead Pharmaceuticals Reports Long-Term Efficacy, Safety Data for Plozasiran

Arrowhead Pharmaceuticals reports long-term phase 2b data showing plozasiran reduces triglycerides by 83 percent in sHTG patients, with no pancreatitis events and sustained improvements in lipid markers and safety.

Global Pharma | 30/03/2026 | By News Bureau |  186

Artelo Biosciences Expands ART27.13 as Companion Therapy to GLP-1 Treatments

Artelo Biosciences advances ART27.13 as a potential companion therapy to GLP-1 treatments, aiming to preserve muscle mass during weight loss, supported by new preclinical studies, patent filings and published research.

Global Pharma | 26/03/2026 | By News Bureau |  122

Marvel Biosciences Selects Novotech as CRO for MB-204 Phase-I Trial

Marvel Biosciences selects Novotech as CRO for its phase-I clinical trial of MB-204, a patented adenosine A2A antagonist, following successful cGMP synthesis and GLP toxicology studies.

Global Pharma | 25/03/2026 | By News Bureau |  173

Novartis Presents New Data on Skin Disease Treatment at AAD 2026

Novartis presents new AAD 2026 data showing early symptom relief and long-term control in skin diseases, with Rhapsido REMIX analysis in CSU and Cosentyx data in hidradenitis suppurativa and psoriasis.

Global Pharma | 25/03/2026 | By News Bureau |  323

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.

Global Pharma | 24/03/2026 | By News Bureau |  141

Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer

Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).

Global Pharma | 21/03/2026 | By News Bureau |  100